Literature DB >> 8485067

A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

S Di Somma1, V Liguori, M Petitto, A Carotenuto, D Bokor, O de Divitiis, M de Divitiis.   

Abstract

The antianginal activities of nicorandil, 10 and 20 mg bid, and metoprolol, 100 mg bid, were compared in patients with stable effort angina pectoris in a randomized, double-blind parallel group study lasting 7 weeks. Twenty patients were enrolled into the trial and 16 patients completed the study. To evaluate the anti-ischemic effects of the two drugs, a treadmill exercise test was performed after a 1-week placebo run-in period and 6 weeks of treatment. On the same occasions, weekly sublingual nitroglycerin consumption and the number of anginal attacks were also recorded in the patient's diary. The total duration of exercise increased significantly with both nicorandil, 10 and 20 mg, and metoprolol (p < 0.01). Similar improvements were observed in the time to onset of ischemia with both treatments (p < 0.01). The double product at maximal comparable workload (MAX 1) was reduced with the two drugs (p < 0.05 for nicorandil and p < 0.01 for metoprolol), while at the maximal exercise time (MAX 2) it was reduced with metoprolol (p < 0.01) and slightly but not significantly increased with both doses of nicorandil. Weekly sublingual nitroglycerin consumption and anginal attacks were also significantly reduced a similar manner by both treatments (p < 0.01). In conclusion, nicorandil, 10 and 20 mg bid, exerted an anti-ischemic effect comparable with that of metoprolol in patients with stable effort angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485067     DOI: 10.1007/bf00878320

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  22 in total

1.  Acute hemodynamic effects of single-dose nicorandil in coronary artery disease.

Authors:  D J Coltart; M Signy
Journal:  Am J Cardiol       Date:  1989-06-20       Impact factor: 2.778

Review 2.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

3.  Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol.

Authors:  K Kobayashi; T Hakuta
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

4.  Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin.

Authors:  T Aizawa; K Ogasawara; K Kato
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

5.  Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test.

Authors:  K Kato; H Asanoi; C Wakabayashi; S Hosoda; A Shiina; K Hosono; A Kurita; K Seki; K Ishida; A Kuroiwa
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

6.  Hemodynamic effects of nicorandil, isosorbide dinitrate, and dihydralazine in healthy volunteers.

Authors:  G G Belz; J H Matthews; A Beck; G Wagner; B Schneider
Journal:  J Cardiovasc Pharmacol       Date:  1985 Nov-Dec       Impact factor: 3.105

7.  Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism.

Authors:  M Kinoshita; K Hashimoto; Y Ohbayashi; T Inoue; H Taguchi; K Mitsunami
Journal:  Am J Cardiol       Date:  1989-06-20       Impact factor: 2.778

Review 8.  Nicorandil as a hybrid between nitrates and potassium channel activators.

Authors:  N Taira
Journal:  Am J Cardiol       Date:  1989-06-20       Impact factor: 2.778

9.  Effects of SG-75 (nicorandil) on electrical activity of canine cardiac Purkinje fibers: possible increase in potassium conductance.

Authors:  S Imanishi; M Arita; T Kiyosue; M Aomine
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

10.  Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris.

Authors:  M Kinoshita; S Nishikawa; M Sawamura; S Yamaguchi; K Mitsunami; M Itoh; M Motomura; K Bito; I Mashiro; S Kawakita
Journal:  Am J Cardiol       Date:  1986-10-01       Impact factor: 2.778

View more
  14 in total

1.  Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management.

Authors: 
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

2.  Impact of nicorandil in angina: subgroup analyses.

Authors: 
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 3.  K(ATP) channel therapeutics at the bedside.

Authors:  A Jahangir; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

Review 4.  Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Eur Cardiol       Date:  2018-08

5.  [Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease].

Authors:  C Bickel; H J Rupprecht; A Tyrtania; J Rörig; J Meyer
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 6.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

Review 7.  Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Authors:  A Markham; G L Plosker; K L Goa
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 8.  Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.

Authors:  C Knight; H Purcell; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 9.  Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Authors:  Dene Simpson; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Treatment of refractory angina in patients not suitable for revascularization.

Authors:  Timothy D Henry; Daniel Satran; E Marc Jolicoeur
Journal:  Nat Rev Cardiol       Date:  2013-12-24       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.